Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial

著者: Marin H. Kollef, Martin Nováček, Ülo Kivistik, Álvaro Réa-Neto, Nobuaki Shime, Ignacio Martín‐Loeches, Jean‐François Timsit, Richard G. Wunderink, Christopher Bruno, Jennifer A. Huntington, Gina Lin, Brian Yu, Joan R. Butterton, Elizabeth G. Rhee - The Lancet 2019 被引用: 346